For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

https://www.mycme.com/learn/course/recent-research-into-biologics-in-asthma-10830

Program Description

This podcast activity provides an in-depth review of several recent trials in severe asthma management, highlighting the ongoing shift in asthma precision medicine towards identifying the right patients for the right treatments. Clinicians will examine clinical data from the NIMBLE trial (depemokimab), alongside the WAYFINDER trial (tezepelumab), as well ZEPHYR 5 (benralizumab), REMOMEPO (mepolizumab), VESTIGE (dupilumab) and VALLIANT (verekitug). This activity will grant clinicians critical insights to move beyond simple exacerbation reduction and precisely align advanced biologic therapies with the underlying cellular biology driving each patient's symptoms.

Educational Objective

At the conclusion of this activity, participants should be better able to:

Review recent updates in the asthma literature, including recent guideline revisions and evolving clinical trial data for newer biologic therapies.

Accredited Providers

The National Association for Continuing Education in partnership with the Association for Pulmonary Advanced Practice Providers (APAPP).

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 

Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).

Faculty

Cedric Rutland, BS, MD, FCCP
Volunteer Faculty
University of California
Pulmonary Critical Care Internal Medicine, Producer
Rutland Medical Group
Newport Critical Care Physicians
Lake Forest, CA

Dr. Rutland has disclosed the following financial relationships:
Consultant: Sanofi (asthma, diabetes, NP, RSV, AD), Boehringer Ingelheim (IPF, PPF), Regeneron (asthma, diabetes, NP, RSV, AD), Chiesi (asthma), Baxter (bronchiectasis), Insmed (bronchiectasis), AstraZeneca (asthma, cough)
Advisor/Advisory Board: Sanofi (asthma, AD, NP), Regeneron (asthma, AD), Chiesi (asthma), Boehringer Ingelheim (IPF, PPF), AstraZeneca (asthma, cough)
Speaker: Sanofi (asthma, NP, AD, AFRS, urticaria, EoE), Regeneron (asthma, NP, AD, AFRS, urticaria, EoE), Boehringer Ingelheim (IPF, PPF), AstraZeneca (asthma, cough), Chiesi (asthma), Baxter (bronchiectasis)

These relationships have ended within last 24 months:
Consultant: GSK (asthma, cough, RSV)
Advisor/Advisory Board: GSK (asthma, cough, RSV)
Speaker: GSK (asthma, cough, RSV)

Diego J. Maselli, MD, FCCP, ATSF
Professor and Chief
Division of Pulmonary Diseases & Critical Care
UT Health at San Antonio
Director, Respiratory Care, University Health System
Director, Severe Asthma Program, University Health System
San Antonio, TX

Dr. Maselli has disclosed the following financial relationships:
Consultant: AstraZeneca (asthma, COPD), Sanofi/Regeneron (asthma, COPD), GSK ( asthma, COPD), Amgen (asthma, COPD), Insmed (bronchiectasis)
Speaker: GSK (asthma, COPD), AstraZeneca (asthma, COPD), Amgen (asthma, COPD), Sanofi/Regeneron (asthma, COPD)

All of the relevant financial relationships listed for these individuals have been mitigated.

Nurse Planner and Peer Reviewer

Marjorie Crabtree, DNP, FNP, ANP
Haymarket Medical Education
Steering Committee
Nurse Practitioner Healthcare Foundation
Accredited Provider Program Director
Bellevue, WA

Dr. Crabtree has no relevant conflicts of interest with any ACCME-defined ineligible company.

Accredited Provider Disclosure

NACE staff has no relevant financial relationships to disclose.

Intended Audience

Pulmonology, allergy/immunology, and critical care clinicians (physicians, nurse practitioners, and physician associates), as well as primary care and geriatric medicine clinicians caring for patients with asthma.

Commercial Supporters

This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

https://www.mycme.com/courses/emerging-agents-in-pulmonary-arterial-hypertension-10829

Program Description

This enduring educational activity provides a comprehensive update on late stage agents being researched for the management of pulmonary arterial hypertension (PAH). Led by expert faculty, the program shifts the clinical focus from traditional vasodilators to novel investigational therapies that directly target the underlying cellular pathways responsible for pulmonary vascular remodeling and disease progression. Clinicians will gain critical insights into the mechanisms of action, latest clinical trial data, and real-world practice implications of these emerging therapeutic classes to better address unmet needs in contemporary care.

At the conclusion of this activity, participants should be better able to:

Discuss clinical trial data and potential clinical utility of emerging agents in PAH.

Accredited Providers

The National Association for Continuing Education in partnership with the Association for Pulmonary Advanced Practice Providers (APAPP).

Accreditation Statement

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 

Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).

Intended Audience

Pulmonology clinicians (physicians, nurse practitioners, and physician associates), cardiology clinicians, and primary care clinicians caring for patients with or at risk for PAH.

Faculty

Ioana Preston, MD
Director Pulmonary Hypertension Center
Lahey Hospital and Medical Center
UMASS Chan Medical School
Burlington, MA

Dr. Preston has disclosed the following financial relationships:
Consultant: Gossamer Bio, Insmed, Janssen Pharmaceuticals, Keros Therapeutics, Liquidia Technologies, Merck & Co./Acceleron Pharma, Respira Technologies, United Therapeutics Corporation
Contracted Research: Gossamer, Janssen Pharmaceuticals, Merck & Co./Acceleron Pharma, Novartis, United Therapeutics Corporation
Data and Safety Monitoring Board (DSMB): Tectonic Therapeutic

All of her disclosures are related to PH.

Jean Elwing, MD
Professor of Medicine, University of Cincinnati College of Medicine
Director, Pulmonary Hypertension Program, University of Cincinnati 
Pulmonary, Critical Care and Sleep Medicine
Cincinnati, OH

Dr. Elwing has disclosed the following financial relationships:
Consultant: Gossamer Bio (pulmonary hypertension), Insmed (pulmonary hypertension), Liquidia (pulmonary hypertension), United Therapeutics (pulmonary hypertension)
Speaker: Merck (pulmonary hypertension)
Contracted Research: Acceleron/Merck (pulmonary hypertension), Gossamer Bio (pulmonary hypertension), Inhibikase (pulmonary hypertension), Insmed (pulmonary hypertension), Lung LLC (pulmonary hypertension), Novartis (pulmonary hypertension), NS Pharma (pulmonary hypertension), Pharmosa/Liquidia (pulmonary hypertension), Pulmovant (pulmonary hypertension), Regeneron (pulmonary hypertension), United Therapeutics (pulmonary hypertension)

These relationships ended within the last 24 months:
Consultant: Inhibikase (pulmonary hypertension), Janssen/Actelion/Johnson & Johnson (pulmonary hypertension), Merck (pulmonary hypertension)
Advisor/Advisory Board: Gossamer Bio (pulmonary hypertension), Inhibikase (pulmonary hypertension), Merck (pulmonary hypertension), United Therapeutics (pulmonary hypertension)
Speaker: United Therapeutics (pulmonary hypertension)

All of the relevant financial relationships listed for these individuals have been mitigated.

Nurse Planner and Peer Reviewer

Marjorie Crabtree, DNP, FNP, ANP
Haymarket Medical Education
Steering Committee
Nurse Practitioner Healthcare Foundation
Accredited Provider Program Director
Bellevue, WA

Dr. Crabtree has no relevant conflicts of interest with any ACCME-defined ineligible company.

Accredited Provider Disclosure

NACE staff have no relevant financial relationships to disclose.

Commercial Supporters

This activity is supported by an independent educational grant from Insmed and an independent educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

https://www.mycme.com/courses/the-evolving-role-of-antibody-drug-conjugates-in-metastatic-triple-negative-breast-cancer-10800

Summary
This CME/CE-certified podcast will provide multidisciplinary clinicians with an evidence-based update on the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline treatment of metastatic triple-negative breast cancer. A medical and an ocular oncology specialist review the latest efficacy and safety data from pivotal clinical trials evaluating ADCs, their integration into contemporary treatment algorithms, and guideline recommendations based on PD-L1 status, BRCA mutation status, and immunotherapy eligibility. Learners will explore key factors influencing treatment selection, compare the benefits and limitations of more established therapeutic options, and examine practical strategies for preventing, recognizing, and managing ADC-associated toxicities. Special emphasis will be placed on multidisciplinary approaches to the management of ocular adverse events and other clinically significant toxicities to optimize patient outcomes and support safe implementation of these therapies in clinical practice.

Learning Objectives

• Evaluate the current and emerging clinical evidence surrounding the use of trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugates (ADCs) in the first-line treatment of metastatic triple-negative breast cancer (TNBC)
• Integrate TROP2-directed ADCs into frontline treatment regimens for metastatic TNBC based on the latest clinical evidence, guidelines, and patient- and tumor-specific factors
• Apply multidisciplinary and patient-centric strategies for the prevention, recognition, and management of toxicities associated with the use of TROP2-directed ADCs in patients with metastatic TNBC

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology). 

For additional information about the accreditation of this program, please contact NACE at [email protected].

Faculty and Moderator 

Aditya Bardia, MD
Program Director, Breast Medical Oncology, UCLA
Professor of Medicine, UCLA
Los Angeles, CA

Dr. Bardia has disclosed the following financial relationships:
Consultant: Alyssum, AstraZeneca/Daiichi, BMS, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Vyome
Advisor/Advisory Board: Alyssum, AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Vyome
Contracted Research: AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer
Stock options: Vyome (immuno-inflammatory and rare diseases)

All of his consultant, advisor/advisory board, and contracted research disclosures are related to cancer.

Maura Di Nicola, MD
Assistant Professor of Ophthalmology
Bascom Palmer Eye Institute
Medical Director of Imaging and Echography
Bascom Palmer Eye Institute
Miami, FL

Dr. Di Nicola has disclosed the following financial relationships:
Consultant: AbbVie (ophthalmology), SpringWorks Therapeutics (oncology)
Advisor/Advisory Board: AbbVie (ophthalmology)
Research Grant: Castle Biosciences (ocular oncology)

Please review additional planner disclosures here.

Disclosure of Commercial Support
This educational activity is supported by a medical education grant from AstraZeneca Pharmaceuticals and a medical education grant from Daiichi Sankyo, Inc.

Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:

1. Orforglipron for maintenance of body weight reduction  - Nature Medicine
2026. Discussion by:

Guest:
Joe Gonella, MD 
Resident - Abington Family Medicine Residency Program 
Jefferson Health

2. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN) Lancet 2026.  Discussion by: 

Guest:
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney  Kimmel  Medical College Thomas Jefferson University
Associate Director - Family Medicine Residency Program
Jefferson Health – Abington

3. Survival and Recurrence with GLP-1 Receptor Agonists in Breast Cancer" – JAMA Network Open Discussion by:

Guest:
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney  Kimmel  Medical College Thomas Jefferson University
Associate Director - Family Medicine Residency Program
Jefferson Health – Abington

4. In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.   NEJM 2026 Discussion by:

Guest:
Alex Sauer, MD 
Resident - Abington Family Medicine Residency Program
Jefferson Health

Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. 

This Podcast Episode does not offer CME/CE Credit. 

Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:

1. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes Results From the VESALIUS-CV Trial. JAMA 2026. Discussion by:

Guest:
Jessica Stieritz, MD
Resident - Abington Family Medicine Residency Program 
Jefferson Health

2. A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomized controlled trial. Lancet Rheumatology 2026. Discussion by:

Guest:
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney  Kimmel  Medical College Thomas Jefferson University
Associate Director - Family Medicine Residency Program
Jefferson Health – Abington

3. Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients. NEJM 2026 Discussion by: 

Guest:
Steven Leonard, MD 
Resident - Abington Family Medicine Residency Program 
Jefferson Health

Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. 

This Podcast Episode does not offer CME/CE Credit. 

Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:

1. Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. BMJ 2026. Discussion by:

Guest:
Susan Kucher, MD
Program Director - Abington Family Medicine Residency Program 
Jefferson Health

2. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes Results From the VESALIUS-CV Trial. JAMA. Discussion by:

Guest:
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney  Kimmel  Medical College Thomas Jefferson University
Associate Director - Family Medicine Residency Program
Jefferson Health – Abington

3. Prevalence of Youth Overweight, Obesity, and Severe Obesity. JAMA Network Open. Discussion by:  

Guest:
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney  Kimmel  Medical College Thomas Jefferson University
Associate Director - Family Medicine Residency Program
Jefferson Health – Abington

4. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. New England Journal of Medicine 2026. Discussion by:

Guest:
Griffin Johnson, MD
Resident - Abington Family Medicine Residency Program 
Jefferson Health

Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. 

This Podcast Episode does not offer CME/CE Credit. 

Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.